SpectaCell Raises €6M to Advance Cell Therapy Analytics

The big picture: SpectaCell, a new Ghent-based startup specializing in next-generation cell therapy analytics, has officially launched with €6 million in Seed funding. The company, which spun out of imec, VIB, and Ghent University, aims to revolutionize drug development and manufacturing. SpectaCell plans to use this capital to fund further development and commercialization of its platform with pharmaceutical and biotechnology partners.

Why it matters:

• Predicting efficacy: Immunotherapies offer new ways to treat cancer and immune system diseases, but predicting which candidates will work in patients and ensuring consistent production remain major challenges.
• Critical gaps: Slow and fragmented testing processes create critical gaps in understanding treatment mechanisms, delaying crucial decisions while patients await new therapies.
• Accelerating innovation: SpectaCell’s platform seeks to provide detailed insights and rapid results, enabling researchers to identify promising drug candidates earlier and accelerate the development of better medicines.

How it works:

• Proprietary technology: SpectaCell’s platform combines digital imaging and data analysis to precisely measure how treatments affect individual cells, offering a clearer view than traditional methods.
• High-resolution tracking: The technology utilizes chip-based imaging to track large numbers of individual cells and their interactions directly, at high resolution, and over time, without relying on fluorescent labels that can interfere with cell behavior.
• Streamlined workflow: The company is developing an easy-to-use, cartridge-based instrument designed to deliver these critical insights in hours rather than days, connecting research with manufacturing for a seamless workflow.

The catch: The cell therapy analytics market is highly competitive, with numerous established players and emerging startups vying to solve the challenges of drug development and manufacturing. SpectaCell’s success will depend on its ability to demonstrate superior accuracy, speed, and ease of integration compared to existing solutions, particularly in a landscape where biopharma companies are heavily invested in their current workflows.

Key Facts

• Company: SpectaCell
• Amount: €6M
• Round: Seed
• Investors: imec.xpand (lead), PMV’s Flanders Future Tech Fund, InnovationQuarter Capital, Qbic, VIB
• Founders: Mathieu Rabaey, Veronique De Vroey, Jan Van de Velde, Tony Montoye
• Announced: 2026-10-01
• Sector: Cell Therapy Analytics
• Headquarters: Ghent, Belgium